Enterprise Value to EBITDA Ratio: Sunshine Biopharma (SBFM)
Sunshine Biopharma (SBFM) is developing innovative methods to combat tumors and viruses, with the creation of mRNA therapies and the sale of licenses to pharma behemoths serving as the key drivers. The operating model is based on outsourcing production in North America, which minimizes capital expenditures. However, limited capital and early-stage testing weaken patent protection. This price chart with the 0.00 metric confirms the current fundamental state of the business.
Analytical breakdowns for Sunshine Biopharma
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity Sunshine Biopharma|SBFM - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Sunshine Biopharma|SBFM - Company Aggregate Debts|Debt to Book Capitalization Ratio Sunshine Biopharma, Inc.|SBFM - Company Long-Term Indebtedness|Company Short-Term Debt Sunshine Biopharma|Quick Ratio sunshinebiopharma.com
- business earnings and investment ratios data:
SBFM - Final Profit|Projected Future Earnings Sunshine Biopharma|SBFM - Business Payback Period|Future Price to Earnings Sunshine Biopharma, Inc.|SBFM - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Sunshine Biopharma, Inc.|SBFM - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Sunshine Biopharma|SBFM - Earnings per share for the trailing year|Quarterly EPS earnings growth sunshinebiopharma.com|SBFM - Earnings per share growth in current year|Earnings growth forecast for next year Sunshine Biopharma
Fundamental company analysis:SBFM (Sunshine Biopharma, Inc.)
The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest. By analyzing the EV/EBITDA valuation ratio over time, an investor determines the asset's payback period while accounting for the debt load. For Sunshine Biopharma (SBFM), this indicator highlights the absence of current operating profit, as the development of anti-tumor drugs is fully funded by external capital.
Competitor analysis for Sunshine Biopharma
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|Total Company Value to Operating Income Before Depreciation Ratio delcath.com|Y-mAbs Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Biosciences Inc AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ARAY (Accuray, Inc.) - Enterprise Value to Operating Income Before Depreciation|sellaslifesciences.com (SLS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACTU - Total Company Value to Operating Income Before Depreciation Ratio|CTOR (Citius Oncology) - EV/EBITDA Multiple|HURA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TARA|Total Company Value to Operating Income Before Depreciation Ratio Fate Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aadi Bioscience WHWK|TCRX: Enterprise Value to Operating Income Before Depreciation|Champions Oncology Corp - EV/EBITDA Multiple|Company Value to EBITDA XBiotech Inc.|CVM (cel-sci.com) - Enterprise Value to EBITDA Ratio|OS Therapies, Inc. - Business Value to Operating Income Before Depreciation|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ARTV|EV/EBITDA Multiple ANL|Total Company Value to Operating Income Before Depreciation Ratio Veru Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Tx TPST|Xilio Therapeutics Inc (XLO) - Company Value to EBITDA|RENB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio MURA|KAPA: EV/EBITDA Multiple|OnKure Therapeutics - Business Value to Operating Income Before Depreciation|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|EV/EBITDA Multiple Curis Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apollomics, Inc. (APLM)|THAR (tharimmune.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Advanced Biomed ADVB|GNPX - Enterprise Value to EBITDA Ratio|Calidi Bio - EV/EBITDA Multiple|XBIO - EV/EBITDA Multiple|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PPBT - Total Company Value to Operating Income Before Depreciation Ratio|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BGNE|EV/EBITDA Multiple CKPT|ELEV: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|IKNA - Enterprise Value to EBITDA Ratio|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MOR: EV/EBITDA Multiple|NAYA Biosciences Corp (NAYA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
